AstraZeneca's Farxiga Receives the US FDA's Breakthrough Therapy Designation for Chronic Kidney Disease
Shots:
- The BT destination follows P-lll DAPA-CKD assessing Farxiga (10mg- qd) + SOC vs PBO in 4-304 patients with CKD Stages 2-4 and elevated urinary albumin excretion- with/ out T2D across 21 countries
- Results: 39% reduction in the composite measure of worsening of renal function or risk of CV or renal death; 31% reduction in death from any cause
- Farxiga (PO- qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control- weight loss- and BP reduction
Ref: AstraZeneca | Image: Mint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com